Matching Placebo (E2814)

DRUG2 trials

Sponsors

Washington University School of Medicine

Conditions

Alzheimers DiseaseAlzheimers Disease, FamilialDementia

Phase 2

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001

Active, not recruitingNCT01760005

Washington University School of MedicineAlzheimers Disease, Alzheimers Disease, Familial, Dementia

Start: 2012-12-01End: 2028-07-01Target: 490Updated: 2026-02-13

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)

Active, not recruitingNCT05269394

Washington University School of MedicineAlzheimers Disease, Alzheimers Disease, Familial, Dementia

Start: 2021-12-22End: 2028-07-01Updated: 2026-02-13

Related Papers

Lecanemab in DIAD: 6‐Month Amyloid PET Results from the DIAN‐TU‐001 Trial

Alzheimer s & Dementia2025-12-01

DIAN‐TU‐001 Trial (Tau NexGen) Rationale and Enrollment Experience

Alzheimer s & Dementia2025-12-01

The relationship of soluble tau species with Alzheimer's disease amyloid plaque removal and tau pathology

Alzheimer s & Dementia2025-09-011 citations

Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial.

2025-04-0117 citations

MRI and PET findings with long‐term gantenerumab treatment: results from the DIAN‐TU trial

Alzheimer s & Dementia2024-12-01

Delaying symptom onset in Dominantly Inherited Alzheimer’s Disease: Long‐term gantenerumab treatment results from the DIAN‐TU trial

Alzheimer s & Dementia2024-12-01

E2814: an anti‐tau therapy engages its CNS target and affects the downstream tangle‐specific biomarker MTBR‐tau243 in Dominantly Inherited Alzheimer’s Disease

Alzheimer s & Dementia2023-12-019 citations

Longitudinal head-to-head comparison of <sup>11</sup>C-PiB and <sup>18</sup>F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer's disease.

2023-04-0519 citations

Overview of dominantly inherited AD and top‐line DIAN‐TU results of solanezumab and gantenerumab

Alzheimer s & Dementia2020-12-015 citations